ArticleCureus2022

Use of Sodium-Glucose Transport Protein 2 (SGLT2) Inhibitor Remogliflozin and Possibility of Acute Kidney Injury in Type-2 Diabetes.

Rajesh Jain et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.